These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 18066039)

  • 1. The growth and potential of human antiviral monoclonal antibody therapeutics.
    Marasco WA; Sui J
    Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the development and approval of monoclonal antibodies for viral infections.
    Reichert JM
    BioDrugs; 2007; 21(1):1-7. PubMed ID: 17263584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies for prophylaxis and therapy of infectious diseases.
    ter Meulen J
    Expert Opin Emerg Drugs; 2007 Nov; 12(4):525-40. PubMed ID: 17979597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
    Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.
    Zhu Z; Dimitrov AS; Chakraborti S; Dimitrova D; Xiao X; Broder CC; Dimitrov DS
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):57-66. PubMed ID: 16441209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies against viruses and bacteria: a survey of patents.
    Xiao X; Dimitrov DS
    Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):171-7. PubMed ID: 18221173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain.
    Gao R; Sreenivasan CC; Sheng Z; Hause BM; Zhou B; Wentworth DE; Clement T; Rausch D; Brunick C; Christopher-Hennings J; Wu H; Bausch CL; Sullivan EJ; Hoppe AD; Huber VC; Wang D; Li F
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Pediatr Pol; 2013; 88(5):T15-T23. PubMed ID: 32287402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
    Pelegrin M; Naranjo-Gomez M; Piechaczyk M
    Trends Microbiol; 2015 Oct; 23(10):653-665. PubMed ID: 26433697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
    Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of Neutralizing Monoclonal Antibodies to Human Astrovirus and Characterization of Virus Variants That Escape Neutralization.
    Espinosa R; López T; Bogdanoff WA; Espinoza MA; López S; DuBois RM; Arias CF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies.
    Andrews CD; Huang Y; Ho DD; Liberatore RA
    Emerg Microbes Infect; 2020 Dec; 9(1):1523-1533. PubMed ID: 32579067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies as innovative therapeutics.
    Reichert JM
    Curr Pharm Biotechnol; 2008 Dec; 9(6):423-30. PubMed ID: 19075682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.
    Crowe JE
    Cell Host Microbe; 2017 Aug; 22(2):193-206. PubMed ID: 28799905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc
    Yu L; Liu X; Ye X; Su W; Zhang X; Deng W; Luo J; Xiang M; Guo W; Zhang S; Xu W; Yan Q; Wang Q; Cui Y; Wu C; Guo W; Niu X; Zhang F; Lei C; Qu L; Chen L; Feng L
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Palivizumab in viral respiratory infections].
    Grell L
    Internist (Berl); 2005 Apr; 46(4):474; author reply 474, 476. PubMed ID: 15717184
    [No Abstract]   [Full Text] [Related]  

  • 20. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
    Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
    Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.